Cytological research
Recent research in cancer vaccines has made significant strides, with studies in the United States and Germany offering promising insights into the development of effective treatments. While tumor-derived exosomes have been explored as vaccines, scientists have found they can also suppress T-cell signaling molecules and induce apoptosis. In contrast, researchers
Drugs
Pioneering research from Ireland and the United States has shed new light on cancer therapy, focusing on the intricate relationship between cancer cell growth and angiogenesis. Investigators have identified peptides and proteins that can harness the power of vascular endothelial growth factor (VEGF) to selectively kill cancer cells, while also
Drugs
Research investigators from Switzerland, China, and the UK have made significant contributions to the understanding of oncogenesis, shedding light on the molecular mechanisms that govern cancer development. A comprehensive review by Ernst Hafen, published in the Swiss Medical Weekly, provides insight into the role of model organism genetics in understanding
Health care industry
Researchers at Yale University have developed an immunotherapy treatment for cancer that targets both the tumor vasculature and tumor cells, demonstrating promising results in treating human solid tumors. The treatment involves systemic delivery of an immunoconjugate molecule composed of a tumor-targeting domain conjugated to the Fc effector domain of human
Health care industry
A phase II trial involving a prostate cancer vaccine has demonstrated encouraging outcomes, with 58% of participants remaining responsive to treatment after an average follow-up period of 291 and 557 days. The study, published in Prostate, used an autologous dendritic cell vaccine in combination with two human histocompatibility antigen (HLA-A2)
Health care industry
CEL-SCI Corporation announced that the Czech Republic's State Institute for Drug Control has granted permission to start a Phase II clinical trial with CEL-SCI's immunotherapeutic drug, Multikine. This multicenter study, being conducted in Poland and the Czech Republic, aims to enroll 30 patients with squamous cell
Health care industry
Researchers at the University of Padua, Italy, have made a significant breakthrough in cancer therapy with the development of methoxymorpholinyl doxorubicin (MMDX) delivered by interleukin-2 (IL-2)-activated natural killer (NK) cells. In a study published in the British Journal of Cancer, L. Quintieri and colleagues demonstrated the efficacy of this
Pharmaceutical industry
Lorus Therapeutics, through its subsidiary NuChem Pharmaceuticals Inc., has received confirmation from the U.S. National Cancer Institute (NCI) on the in vitro anti-cancer activity of its novel compounds being developed. The NCI has also decided to conduct further testing on these compounds for anti-cancer efficacy in animal models, based
Pharmaceutical industry
This study presents a high-efficacy chemotherapy regimen for locally advanced and metastatic head and neck cancer. Fifty patients with squamous cell carcinoma of the head and neck (SCCHN) were treated with a combination of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil. The treatment resulted in an overall response rate of 80%
